Filing Flows › Iovance Biotherapeutics (IOVA) › Q1 2025
Iovance Biotherapeutics (IOVA) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 8, 2025
Iovance Biotherapeutics (IOVA) reported revenue of $49.3M for the first quarter 2025 (Q1 2025), up 69-fold from a year earlier and -33% from the quarter before. Operating margin was -245.8%, net loss $116M (235.5% of revenue).
Iovance Biotherapeutics, Q1 2025: revenue $49.3M (69× year over year), operating margin -245.8%, net loss $116M, operating cash flow −$104M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $49.3M | -33% | 69× |
| Operating profit | −$121M | — | — |
| Net earnings | −$116M | — | — |
| Operating cash flow | −$104M | — | — |
What changed
Revenue was $49.3M in Q1 2025, up 6798% year over year and down 33% from the previous quarter. Amtagvi was the largest line at 88% of revenue. PROLEUKIN added $5.0M year over year (up 705%), 10% of the total change.
Operating costs exceeded revenue by $121.2M, an operating margin of -245.8%. Total costs grew 44% against revenue growth of 6798%. The fastest-growing cost line was Cost of revenue (+585%). The quarter ended with a net loss of $116.2M, wider than the previous quarter's $78.6M loss.
Operating cash flow was −$103.7M. Non-cash charges added back $2.8M of depreciation and amortization and $22.9M of share-based compensation. Working capital and other items used $13.2M. Capital expenditures of $6.2M exceeded it, leaving free cash flow of −$109.9M.
Questions
What was Iovance Biotherapeutics' revenue in the first quarter 2025?
Iovance Biotherapeutics (IOVA) reported revenue of $49.3M for the first quarter 2025 (Q1 2025), up 69-fold from a year earlier and -33% from the quarter before.
Was Iovance Biotherapeutics profitable in the first quarter 2025?
Operating loss was $121M (-245.8% of revenue) and net loss $116M.